936 related articles for article (PubMed ID: 35595223)
41. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders.
Griffin D; Benadiva C; Kummer N; Budinetz T; Nulsen J; Engmann L
Fertil Steril; 2012 Jun; 97(6):1316-20. PubMed ID: 22480822
[TBL] [Abstract][Full Text] [Related]
42. Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve.
Lin MH; Wu FS; Hwu YM; Lee RK; Li RS; Li SH
Reprod Biol Endocrinol; 2019 Jan; 17(1):7. PubMed ID: 30609935
[TBL] [Abstract][Full Text] [Related]
43. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
[TBL] [Abstract][Full Text] [Related]
44. The use of GnRH-agonist trigger for the final maturation of oocytes in normal and low responders undergoing planned oocyte cryopreservation.
Maslow BL; Guarnaccia M; Stefanacci C; Ramirez L; Klein JU
Hum Reprod; 2020 May; 35(5):1054-1060. PubMed ID: 32406915
[TBL] [Abstract][Full Text] [Related]
45. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.
Abbara A; Clarke S; Islam R; Prague JK; Comninos AN; Narayanaswamy S; Papadopoulou D; Roberts R; Izzi-Engbeaya C; Ratnasabapathy R; Nesbitt A; Vimalesvaran S; Salim R; Lavery SA; Bloom SR; Huson L; Trew GH; Dhillo WS
Hum Reprod; 2017 Sep; 32(9):1915-1924. PubMed ID: 28854728
[TBL] [Abstract][Full Text] [Related]
46. Comparative study between single versus dual trigger for poor responders in GnRH-antagonist ICSI cycles: A randomized controlled study.
Maged AM; Ragab MA; Shohayeb A; Saber W; Ekladious S; Hussein EA; El-Mazny A; Hany A
Int J Gynaecol Obstet; 2021 Mar; 152(3):395-400. PubMed ID: 33011968
[TBL] [Abstract][Full Text] [Related]
47. The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF.
Massin N; Abdennebi I; Porcu-Buisson G; Chevalier N; Descat E; Piétin-Vialle C; Goro S; Brussieux M; Pinto M; Pasquier M; Bry-Gauillard H
Hum Reprod; 2023 May; 38(5):927-937. PubMed ID: 36864699
[TBL] [Abstract][Full Text] [Related]
48. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
[TBL] [Abstract][Full Text] [Related]
49. Cycle regimens for frozen-thawed embryo transfer.
Ghobara T; Gelbaya TA; Ayeleke RO
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD003414. PubMed ID: 28675921
[TBL] [Abstract][Full Text] [Related]
50. Dual trigger of final oocyte maturation in poor ovarian responders undergoing IVF/ICSI cycles.
Zhang J; Wang Y; Mao X; Chen Q; Hong Q; Cai R; Zhang S; Kuang Y
Reprod Biomed Online; 2017 Dec; 35(6):701-707. PubMed ID: 28993105
[TBL] [Abstract][Full Text] [Related]
51. Triggering with 1,500 IU of human chorionic gonadotropin plus follicle-stimulating hormone compared to a standard human chorionic gonadotropin trigger dose for oocyte competence in in vitro fertilization cycles: a randomized, double-blinded, controlled noninferiority trial.
Anaya Y; Cakmak H; Mata DA; Letourneau J; Zhang L; Lenhart N; Juarez-Hernandez F; Jalalian L; Cedars MI; Rosen M
Fertil Steril; 2022 Aug; 118(2):266-278. PubMed ID: 35705380
[TBL] [Abstract][Full Text] [Related]
52. Equivalent live-birth rate in antagonist IVF/ICSI protocol after oocyte triggering with GnRH agonist supplemented with 1500 r-hCG the day of oocyte retrieval vs r-hCG : A case-control study.
Cherrière F; Arvis P; Le Pabic E; Bidet M; Jaffré F; Guivarc'h-Levêque A
J Gynecol Obstet Hum Reprod; 2020 Jun; 49(6):101702. PubMed ID: 32018042
[TBL] [Abstract][Full Text] [Related]
53. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?
Drakopoulos P; Blockeel C; Stoop D; Camus M; de Vos M; Tournaye H; Polyzos NP
Hum Reprod; 2016 Feb; 31(2):370-6. PubMed ID: 26724797
[TBL] [Abstract][Full Text] [Related]
54. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
[TBL] [Abstract][Full Text] [Related]
55. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
56. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist.
Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y
Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046
[TBL] [Abstract][Full Text] [Related]
57. Effect of Dual Trigger In Vitro Fertilization and Intracytoplasmic Sperm Injection During the Gonadotropin-releasing Hormone-Antagonist Cycle on Final Oocyte Maturation and Cumulative Live Birth Rate in Women with Diminished Ovarian Reserve.
Ren YM; Wang YB; Fu M; Zhang QX; Shen H; Han HJ; Gao FM
Curr Med Sci; 2022 Oct; 42(5):1066-1070. PubMed ID: 35997911
[TBL] [Abstract][Full Text] [Related]
58. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction.
Siristatidis CS; Gibreel A; Basios G; Maheshwari A; Bhattacharya S
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD006919. PubMed ID: 26558801
[TBL] [Abstract][Full Text] [Related]
59. Eight weeks of androgen priming by daily low-dose hCG injections before ICSI treatment in women with low ovarian reserve.
Friis Wang N; Bogstad JW; Pors SE; Petersen MR; Pinborg A; Yding Andersen C; Løssl K
Hum Reprod; 2023 Apr; 38(4):716-725. PubMed ID: 36721920
[TBL] [Abstract][Full Text] [Related]
60. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
